life speak

Wellteq Partners With LifeSpeak to Enhance Targeted Wellness Education and Expand Suite of Mental Health Programs

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

  • Integration with Mental Health and Wellbeing Platform Delivers Comprehensive Employee Wellness Support to Wellteq Clients in APAC Market
  • The first programs will target employee sleep and anxiety where research has shown mental health decline in 42% of employees globally since the onset of the COVID-19 pandemic.
  • This integration complements an already compelling market proposition to employers and insurance companies in a fast growing multi-billion-dollar industry.
  • The integrated solution will initially commence across Asia Pacific with the view to geographical expansion in 2022.

WellteQ Digital Health Inc. (CSE:WTEQ) (OTC:WTEQF) (the "Company" or " Wellteq ") is pleased to announce that the Company has partnered with LifeSpeak (TSX: LSPK), the mental health and wellbeing platform for employee and customer-focused organizations, to provide expert-led mental health and wellness education resources to Wellteq customers across the Asia Pacific market (APAC). This partnership leverages Wellteq's digital health ecosystem and LifeSpeak's extensive content library to empower a healthier, happier workforce through personalized wellness.

The integrated partnership enables Wellteq to strengthen its behavior change programs by embedding LifeSpeak's carefully vetted micro-learning educational content into its award-winning digital wellness and data analytics app. The Wellteq app is highly customizable and provides organizations of all sizes with a flexible, simple, and quick-to-launch digital wellness solution that includes features such as digital coaching, gamified challenges, rewards and recognition, and workforce analytics. Wellteq smartphone software is deployed to over 30 countries in 12 languages and is trusted by organizations such as Garmin, UBS, and Willis Towers Watson.

"The impact of the pandemic on mental health and the normalization of dispersed workforces highlights the importance of giving employees anytime, anywhere access to relevant and engaging information that drives better health outcomes," said Scott Montgomery, CEO of Wellteq. "We are excited to partner with LifeSpeak, an organization that has a long history of delivering highly relevant and engaging education on the health and wellbeing issues that most impact individuals in their personal and professional lives. Lifespeak content will be deployed through Wellteq's sophisticated personalisation engine into user programs initially focusing on sleep, anxiety and burnout which are ever-prevalent due to the pandemic. There is substantial need for these support programs."

LifeSpeak has almost two decades of experience creating proprietary assets with leading experts in their fields. All available education resources have been developed to deliver support and education across a wide range of issues, including critical topics such as mental health, addiction, stress management, relationships, nutrition, fitness, and financial health. Access to this relevant content allows Wellteq to provide authorized users with the information and guidance they most need.

"It is essential that organizations take a proactive and preventative approach to mental health issues. Apathy is no longer an option, and it is critical that business leaders support the wellbeing of their people with high-quality educational resources and tools," said Michael Held, CEO, and founder of LifeSpeak. "Our expert-led educational content has helped millions of people across dozens of industries, and we're thrilled to partner with Wellteq, a highly innovative organization that strives to achieve lasting change through ongoing support and coaching of those in need."

About LifeSpeak Inc.

LifeSpeak is a leading software-as-a-service provider of a platform for mental health and total wellbeing education for organizations committed to taking care of their employees and customers. With 17+ years of experience creating and curating thousands of expert-led micro-learning videos and other digital content, LifeSpeak's proprietary library's depth and breadth of easily consumable content helps companies around the world support their people anytime and anywhere. LifeSpeak serves a diverse global client base across many industries and sectors, including Fortune 500 companies, government agencies, insurance providers, and other health technology firms. To learn more, follow LifeSpeak on LinkedIn ( https://www.linkedin.com/company/lifespeak-inc ), or visit www.LifeSpeak.com .

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model, Wellteq currently has two main sectors of customers: employers and insurance companies. Wellteq has secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners, like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare. To learn more, visit www.wellteq.com .

Investor Contact Welteq:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888
LifeSpeak Contact:

Geoff Lopes
fama PR for LifeSpeak
Lifespeak@famapr.com

Forward-Looking Information with respect to LifeSpeak

This news release may contain "forward-looking information" within the meaning of applicable securities legislation, which reflects the LifeSpeak's current expectations regarding future events, including statements with regard to the embedding of the LifeSpeak's resources into the Wellteq Solution. Forward-looking information is based on a number of assumptions and risks, and uncertainties, many of which are beyond the LifeSpeak's control. Such assumptions include the number of users covered by our agreement, and such risks and uncertainties include, but are not limited to, the fact that a fewer number of users may be covered by our agreement than expected, the agreement may not be renewed after its initial term and the other factors discussed under "Risk Factors" in LifeSpeak's Prospectus filed on SEDAR. Actual results could differ materially from those projected herein. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained in this news release is provided as of the date of this news release, and LifeSpeak does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws.

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less

Latest Press Releases

Related News

×